| 新型抗肿瘤药物依曼替尼布 |
| |
| 引用本文： | 梁爽,刘超美. 新型抗肿瘤药物依曼替尼布[J]. 中国新药与临床杂志, 2002, 21(9): 567-569 |
| |
| 作者姓名： | 梁爽 刘超美 |
| |
| 作者单位： | 中国人民解放军第二军医大学药学院,有机化学教研室,上海,200433 |
| |
| 摘 要： | 依曼替尼布是一种新型的 2 苯胺基嘧啶类酪氨酸激酶抑制药 ,用于α 干扰素治疗失败后的慢性髓样白血病 (CML)慢性期病人、加速期病人、急变期病人的治疗。临床研究表明该药对病人血液学缓解及主要细胞分化缓解显著
|
| 关 键 词： | 依曼替尼布 抗肿瘤药 白血病,髓样,慢性 |
| 文章编号： | 1007-7669(2002)09-0567-03 |
A novel antineoplastic agents: imatinib |
| |
| Abstract: | Imatinib is a novel tyrosine protein kinases inhibitor of the 2-phenylaminopyrimidine derivative. It is indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. The clinical studies shows that imatinib is very effective in hematologic response and major cytogenetic response in CML patients. |
| |
| Keywords: | imatinib antineoplastic agents leukemia, myeloid, chronic |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
